Ethanol Induces Skeletal Muscle Autophagy

ConditionAlcoholic Liver Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorThe Cleveland Clinic

About this trial

In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

clinical, biochemical, imaging criteria and liver biopsy where available

Age 18 - 65 years old

Serum liver transaminases (i.e. ALT and AST) 40 IU/L

Normal liver ultrasound

Disqualifiers

Poorly controlled diabetes mellitus (HbA1C>9.5 g/dl)

Untreated Hyper- / hypo- thyroidism

Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL

Active intravenous drug use

Trial population

Histologically characterized patients with alcoholic steatosis, hepatitis and cirrhosis (n=10 each) will be recruited from the liver transplant nutrition clinic or the hepatology inpatient service and their body composition quantified using protocols already established by the PI.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Biopsies
Other intervention
Biopsy will be done on the Vastus Lateralis muscle in all groups

Treatment groups

40 Participants

are divided into 4 treatment groups

Group A: Alcoholic Steatosis1 intervention

Group B: Cirrhosis1 intervention

Group C: Steatohepatitis1 intervention

Group D: controls1 intervention

Trial outcomes

Primary outcomes

Skeletal Muscle Autophagy

We will measure Malonyldialdehyde Acetaldehyde protein adducts to see skeletal muscle proteolysis during a one time muscle biopsy

Time frame

4 hours

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Cleveland Clinic

Lead sponsor

Source ClinicalTrials.gov

Apply now